newsfilter
← Latest News
PR Newswire·

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

ICCM
  • IceCure Medical promoted Shay Levav to Chief Operating Officer to support organizational structure during U.S. commercial expansion.
  • The appointment follows FDA marketing clearance for ProSense® for low-risk breast cancer in October 2025.
  • Levav will continue leading Regulatory Affairs, Quality Assurance, & Clinical Affairs roles he has held since 2020.
  • ProSense® is the first device approved for treating early-stage, low-risk breast cancer in women aged 70+ using adjuvant endocrine therapy.
  • The minimally invasive system uses liquid nitrogen to destroy tumors via freezing, offering benefits like reduced pain & faster recovery.
  • IceCure Medical develops liquid-nitrogen-based cryoablation systems for breast, kidney, bone, & lung cancers.
  • The company anticipates increased commercial traction in the U.S. market under Levav's leadership.